Hepatitis C Virus

New Data On Viramidine And Levovirin Presented

Published in Hepatitis Weekly, December 10th, 2001

New preclinical research on Viramidine, a potential prodrug of ribavirin for chronic hepatitis C, suggests that it might be more effective with fewer side effects than ribavirin.

Ribavirin (Rebetol capsules) is now part of the combination therapy that represents the most effective treatment currently available for this infection. The data were presented November 12, 2001, at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Dallas, Texas.

New data on Levovirin, a L-isomer of ribavirin, which has been shown to have similar immunomodulatory activity as ribavirin but with a much safer profile, were also presented at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry